Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Summary

This trial that is investigating a medication called duvelisib in combination with docetaxel for the treatment of squamous cell carcinoma of the head and neck (SCCHN) that has returned or spread outside the head and neck area. The names of the study drugs involved in this study are: * Duvelisib (PI3K inhibitor) * Docetaxel chemotherapy

Timeline

Start

2021-10-14

Primary completion

2023-10-01

Completion

2024-06-13

Drugs

Indications